Mizuho analyst Ann Hynes raised the firm’s price target on Humana (HUM) to $345 from $300 and keeps an Outperform rating on the shares. The firm adjusted price targets in the healthcare facility and managed care space following an analysis of Medicare Advantage star ratings. The target changes are driven by increased earnings visibility on key issues along with the overall rotation into the healthcare sector, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target raised to $347 from $344 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Positive Outlook for Humana: Buy Rating Supported by Strategic Initiatives and Growth Projections
- Humana updates outside of star ratings positive, says Mizuho
- Humana price target lowered to $245 from $315 at Barclays